An international panel of diabetes experts published guidelines for continuous glucose monitoring (CGM). Presented at the American Diabetes Association’s (ADA’s) 79th Scientific Sessions (2019), the targets are for both research and clinical settings:
• People with Type 1 and Type 2 diabetes: 3.9–10.0mmol/l
• People with Type 1 and Type 2 diabetes during pregnancy: 3.5–7.8mmol/ during pregnancy, along with a set of targets for the time per day (% of CGM readings or minutes/hrs)
• Older and/or high-risk people with Type 1 and Type 2 diabetes: The panel recommends conservative CGM targets, focusing on reducing the percentage of time spent 3.9 mmol/l and preventing excessive hyperglycaemia.
Recommendations are based on data from large pre-CGM clinical trials, CGM randomised controlled trials, and expert opinion. However, the panel agrees that targets must also be personalised to meet individual needs.
The group’s objective was to develop evidence-based, clinical CGM targets to supplement the current measurements for CGM derived times in glucose ranges (within target range, below target range, above target range) in order to provide guidance for in routine clinical care and research.
Presenting author, Professor Tadej Battelinois the Head of the Department of Paediatric and Adolescent Endocrinology at Ljubljana University Medical Centre in Slovenia, and Chair and Professor of Paediatrics at the University of Ljubljana, said: “CGM has the potential to transform diabetes care and our group believes that clear, easy-to-understand and broadly agreed-upon glycaemic targets for time-in-range levels will positively impact short- and long-term diabetes outcomes, particularly if understood and adopted by people with diabetes.”
To read the research CLICK HERE.